DALLAS — October 1, 2026
Spectral AI, Inc. announced completion of the first Site Initiation Visit (SIV) for a clinical study evaluating its FDA-cleared DeepView System™ for Burn Indication in burns involving the head, hands and feet. The SIV was conducted at Pinderfields Hospital in Wakefield, United Kingdom, under the leadership of Dr. Preetha Muthayya, Consultant Burns and Plastic Surgeon and Clinical Lead for Burns. Completion of the site-readiness requirements enables the hospital to begin patient enrollment and represents the operational launch of the study. The prospective study is intended to generate additional clinical evidence supporting a potential label expansion of DeepView into anatomically complex burn areas where assessment of healing potential can influence treatment planning.
DeepView Study Targets Complex Burn Areas
The clinical study is designed to evaluate the DeepView System in adult and pediatric patients with qualifying thermal burns involving the hands, feet or head/face. Participants will undergo imaging with DeepView within 72 hours of injury, with healing outcomes assessed through 21 days. The resulting image dataset will be used for algorithm training and independent validation of system performance. During the study, DeepView will be used in a blinded, observational capacity and will not direct patient care. Spectral AI expects the study to be conducted across multiple sites in the United Kingdom and to be completed in 2027. The study is intended to build additional clinical evidence around DeepView’s performance in anatomical locations that can present particular challenges in burn assessment.
First UK Site Begins Patient Enrollment
Pinderfields Hospital is the first clinical site to complete site initiation for the label expansion study, allowing the site to begin enrolling eligible patients. The hospital is part of the Mid Yorkshire Teaching NHS Trust and provides specialist care for adult and pediatric patients with serious burn injuries. Spectral AI said the completion of the first SIV establishes the operational foundation for the multicenter clinical program. The company is using the study to expand the clinical evidence supporting DeepView beyond its existing burn indication. Data generated through the prospective training and validation program are expected to contribute to evaluation of the system’s performance in burns affecting the head, hands and feet and support the company’s potential regulatory strategy for expanding the device’s labeled use.
Advertisement
DeepView Combines Imaging and AI for Burn Assessment
The DeepView System combines multispectral imaging with a proprietary artificial intelligence algorithm to assess the healing potential of areas within burn wounds. According to Spectral AI, the system was granted De Novo Classification by the U.S. FDA in May 2026 and received its initial UKCA authorization in February 2024. DeepView is designed to provide an objective assessment of whether areas within a burn wound are unlikely to heal within 21 days, potentially providing information that can support earlier treatment decisions. Image acquisition takes approximately 0.2 seconds, while image processing and AI classification take approximately 20–25 seconds. Spectral AI said the system has been trained and tested against a proprietary clinically validated database containing more than 340 billion pixels of burn-wound image data. The new clinical study extends the company’s regulatory and clinical development strategy by generating additional evidence for DeepView in complex burn locations and supporting a potential future label expansion.
Source:Spectral AI,, press release
